Literature DB >> 16115143

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.

Terra L Lasho, Ruben Mesa, D Gary Gilliland, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16115143     DOI： 10.1111/j.1365-2141.2005.05682.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

Review 1.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 2.  Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

Authors:  David Dingli; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 3.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  Cardiovascular Disease, Aging, and Clonal Hematopoiesis.

Authors:  Megan A Evans; Soichi Sano; Kenneth Walsh
Journal:  Annu Rev Pathol       Date:  2019-11-05       Impact factor: 23.472

5.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Authors:  Catriona H M Jamieson; Jason Gotlib; Jeffrey A Durocher; Mark P Chao; M Rajan Mariappan; Marla Lay; Carol Jones; James L Zehnder; Stan L Lilleberg; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

6.  Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization.

Authors:  Hyunjung Kim; Woori Jang; Soyoung Shin; Joonhong Park; Myungshin Kim; Yonggoo Kim; Kyungja Han; Gun Dong Lee; Heusung Won; Young Jun Yang
Journal:  Int J Hematol       Date:  2014-12-10       Impact factor: 2.490

7.  The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors:  Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

8.  The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Randall J Olsen; Cherie H Dunphy; Dennis P O'Malley; Lawrence Rice; April A Ewton; Chung-Che Chang
Journal:  J Hematop       Date:  2008-08-28       Impact factor: 0.196

9.  Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.

Authors:  Ruzhica Bogeska; Heike L Pahl
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

10.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.